9ozf

1-deoxy-D-xylulose 5-phosphate reductoisomerase (IspC) from Acinetobacter baumannii in complex with a Fosmidomycin analog, NADPH, and a magnesium ion

spinqualitylabelsall models 9ozf, resolution 2.00Å Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Structural highlights 9ozf is a 1 chain structure with sequence from Acinetobacter baumannii. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance. Method: X-ray diffraction, Resolution 2Å Ligands: A1CFB, CL, EDO, MG, NDP Resources: FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT Publication Abstract from PubMed Antimicrobial resistance (AMR) is a critical global health crisis, responsible for nearly 5 million deaths in 2019 and projected to impose up to $100 trillion in economic costs by 2050. To address this threat, we are developing new antibiotics targeting the methylerythritol phosphate (MEP) pathway in Acinetobacter baumannii and Klebsiella pneumoniae, major nosocomial pathogens. Our efforts focus on 1-deoxy-d-xylulose 5-phosphate reductoisomerase (IspC/DXR), the committed enzyme in MEP-mediated isoprenoid biosynthesis and absent in humans, making it an attractive therapeutic target. Natural products such as fosmidomycin (FOS) and FR900098 (FR) inhibit IspC but exhibit poor bioavailability. To improve drug-like properties, we synthesized FOS analogs and analyzed their structure-activity relationships (SARs) against recombinant Ab- and Kp-IspC, alongside in vitro susceptibility assays. The most potent analogs, alpha,beta-unsaturated compounds 4b and 16b, inhibited Ab-IspC (AbIspC) with IC(50) values of 0.047 muM and 0.029 muM, and Kp-IspC (KpIspC) with 0.194 muM and 0.054 muM, respectively. These showed MICs of 64 mug/mL for A. baumannii and 512 mug/mL for K. pneumoniae. A prodrug series (1d-8d) demonstrated enhanced activity, with compound 3d exhibiting MICs from 0.25 to 32 mug/mL against A. baumannii. X-ray crystallography of Ab-IspC with selected analogs (2b, 3b, 4b) at 2.0 A resolution provides structural insights to guide future IspC inhibitor optimization. Structure-Activity Relationships among Inhibitors of Acinetobacter baumannii and Klebsiella pneumoniae 1-Deoxy-d-xylulose 5-Phosphate Reductoisomerase (DXR/IspC) - A Promising Target for Antibiotic Development.,Girma M, Dufrisne MB, Sehgal A, Dailey A, Heidel K, Bague D, Wang X, Bartholomew L, Beck R, Kirby S, Ball H, Zainab M, Lee SH, Soojhawon I, Noble SM, Dowd CS, Couch RD ACS Infect Dis. 2026 Mar 12. doi: 10.1021/acsinfecdis.5c00875. PMID:41816984 From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Proteopedia Page Contributors and Editors (what is this?)

OCA